We scan new podcasts and send you the top 5 insights daily.
Dr. Bazanova says acquired MET overexpression can appear after EGFR-targeted therapy, so her standard practice is to repeat biopsy and order both NGS and IHC at progression. That acquired finding can open use of a MET-directed therapy in patients whose earlier biopsy lacked the target.
When a liquid biopsy fails to detect the original EGFR driver mutation in a patient progressing on therapy, it should not be interpreted as the cancer losing its dependency. This result more likely indicates insufficient tumor DNA shedding, signaling that the test is uninformative and a tissue biopsy is needed.
The SAVANNAH study showed that targeting MET amplification after TKI failure is only effective with stringent diagnostic criteria (e.g., IHC 3+ in >90% of cells). Lower cutoffs lead to poor outcomes, highlighting the need for precise biomarker testing to select patients for this therapy.
When patients with EGFR-mutated lung cancer progress on osimertinib, a re-biopsy is essential not just for new genomic markers. It's critical for identifying histologic transformation to small cell or squamous cell cancer, which mandates a complete switch to chemotherapy-based regimens.
While PD-L1 testing by IHC is standard, the diagnostic workup for metastatic NSCLC must now also include IHC for HER2 and CMET. This is because specific antibody-drug conjugates and other agents are now approved and tied directly to the protein expression levels identified by these tests.
Standard Next-Generation Sequencing (NGS) reports often just state "MET amplification" without a specific copy number. To make informed treatment decisions with MET inhibitors, clinicians must proactively contact the testing company's molecular pathology department to obtain this crucial, unlisted data point.
A tumor's genetic profile can evolve under treatment pressure. Retesting tissue or blood upon disease progression may reveal new, actionable mutations (e.g., in BRCA genes) that were absent at diagnosis, thereby opening up new targeted therapy options.
Dr. Bazanova says she orders both in practice because IHC measures surface protein while NGS reads gene-level changes, and each can trigger different therapy. A high IHC result without a MET mutation or amplification is not discordant; it tells a separate part of the tumor's biology.
Cancers evolve under therapeutic pressure, often developing new resistance mutations. Re-testing the tumor via tissue or liquid biopsy upon progression is essential, as it can identify acquired mutations that make the cancer susceptible to a different, next-generation targeted therapy, extending patient survival.
When patients with EGFR-mutant adenocarcinoma transform to small cell lung cancer and then progress on SCLC-directed therapy, it's essential to perform another biopsy. The histology can switch back to the original adenocarcinoma, which would completely alter the next line of treatment, highlighting the tumor's dynamic heterogeneity.
Performing dual analysis with both liquid and tissue biopsies at metastatic diagnosis establishes a comprehensive baseline. This strategy helps differentiate between clonal and later-acquired mutations, enabling more accurate interpretation of subsequent ctDNA monitoring for resistance.